APA (7th ed.) Citation

S, S., H, H., A, J., L, L., A, G., V, H., . . . M, J. (2023). Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood cancer journal, 13(1), 158. https://doi.org/10.1038/s41408-023-00929-0

Chicago Style (17th ed.) Citation

S, Sidana, et al. "Bendamustine Vs. Fludarabine/cyclophosphamide Lymphodepletion Prior to BCMA CAR-T Cell Therapy in Multiple Myeloma." Blood Cancer Journal 13, no. 1 (2023): 158. https://doi.org/10.1038/s41408-023-00929-0.

MLA (9th ed.) Citation

S, Sidana, et al. "Bendamustine Vs. Fludarabine/cyclophosphamide Lymphodepletion Prior to BCMA CAR-T Cell Therapy in Multiple Myeloma." Blood Cancer Journal, vol. 13, no. 1, 2023, p. 158, https://doi.org/10.1038/s41408-023-00929-0.